SCHEMBL267864

SCHEMBL267864

CN(CCO)Cc1ccc(C(=O)Nc2ccc(Cl)cc2C(=O)N/N=C/c2ccc(F)cc2)cc1

nearest known ligand 0.60

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
F10 P00742 15/20 0.60
SLC34A2 O95436 1/20 0.48
SLC34A1 Q06495 1/20 0.48
SLC34A3 Q8N130 1/20 0.48
SLC20A1 Q8WUM9 1/20 0.48
KLKB1 P03952 4/20 0.47
KMT2A Q03164 3/20 0.46
KDM4E B2RXH2 1/20 0.46
ALDH1A1 P00352 1/20 0.46
MAPT P10636 1/20 0.46
RAB9A P51151 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
NPC1 O15118 1/20 0.46
MEN1 O00255 2/20 0.44
LMNA P02545 1/20 0.44
F2 P00734 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL267865 1.00 F10 (0.60) F10SLC34A2SLC34A1SLC34A3SLC20A1
SCHEMBL266830 0.93 F10 (0.62) F10KLKB1KMT2AKDM4EALDH1A1
SCHEMBL266831 0.93 F10 (0.62) F10KLKB1KMT2AKDM4EALDH1A1
SCHEMBL267108 0.92 F10 (0.61) F10KLKB1KMT2AKDM4EALDH1A1
SCHEMBL267107 0.92 F10 (0.61) F10KLKB1KMT2AKDM4EALDH1A1
SCHEMBL265862 0.91 SLC34A2 (0.57) F10SLC34A2SLC34A1SLC34A3SLC20A1
SCHEMBL267969 0.91 SLC34A2 (0.59) F10SLC34A2SLC34A1SLC34A3SLC20A1
SCHEMBL267968 0.91 SLC34A2 (0.59) F10SLC34A2SLC34A1SLC34A3SLC20A1
SCHEMBL265861 0.91 SLC34A2 (0.57) F10SLC34A2SLC34A1SLC34A3SLC20A1
SCHEMBL268730 0.90 F10 (0.52) F10SLC34A2SLC34A1SLC34A3SLC20A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-09-28 US disclosed
EP-1614676-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2006-01-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same SLC10A6, SLC7A1, SLC10A1 F10 188/4885SLC34A2 6/4885SLC34A1 4/4885
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 F10 338/4885SLC34A2 2/4885SLC34A1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.